Clinical Trials associated with Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

NCT03621670 / Active, not recruitingPhase 3

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccines(RIV).

Start Date27 Jul 2018

Sponsor / Collaborator

GSK Plc

NCT03207750 / CompletedPhase 3

Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age

The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age

Start Date14 Sep 2017

Sponsor / Collaborator

GSK Plc

NCT02447978 / CompletedNot Applicable

Duration of Protection Following Five Doses of GlaxoSmithKline's (GSK's) DTaP Vaccines in School Age Children

The purpose of this study is to assess duration of protection for GSK DTaP vaccines in preventing pertussis.

Start Date01 Feb 2015

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

100 Translational Medicine associated with Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

100 Patents (Medical) associated with Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

Literatures (Medical) associated with Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

02 May 2023·Vaccine

Newborn medication adherence and childhood under-immunization in military beneficiaries.

Article

Author: Drumm, Caitlin M ; Vereen, Rasheda J ; Aden, James K

BACKGROUND:

The American Academy of Pediatrics recommends birth doses of vitamin K, erythromycin ointment, and the hepatitis B vaccine, but the relationship between birth medication administration and childhood immunization compliance is understudied. The objective of this study is to evaluate rates of newborn medication administration, and risk factors for refusal in military beneficiaries and determine the relationship between medication refusal and under-immunization at 15 months.

METHODS:

A retrospective chart review was completed for all term and late preterm infants born at Brooke Army Medical Center, San Antonio, TX, from January 1, 2016, to December 31, 2019. The electronic medical record was queried for birth medication administration, maternal age, active-duty status, rank, and birth order. Childhood immunization records were extracted for all patients who continued care at our facility. A patient was considered completely immunized if they had received at least 22 vaccines by 15 months: three doses of the hepatitis B vaccine [Pediarix^TM], two doses of the rotavirus vaccine [Rotarix^TM], four doses of the DTAP vaccine [Pediarix^TM and Acel-Immune^TM], three doses of Haemophilus influenza B vaccine [Pedvaxhib^TM], four doses of pneumococcal [Prevnar 13^TM], three doses of IPV [Pediarix^TM], one dose of measles, mumps, and rubella [MMR^TM], one dose of varicella [Varivax^TM] and one dose of hepatitis A vaccine [Harvix^TM].

RESULTS:

Seven thousand one hundred and forty infants were included; 99.3% received vitamin K, 98.8% received erythromycin ointment, and 93.8% received the hepatitis B vaccine. Refusal of the erythromycin ointment and hepatitis B vaccine was associated with older maternal age and higher birth order. Childhood immunization records were available for 607 infants; 7.2% (n = 44) were under-immunized by 15 months, with no infants being non-immunized. Refusal of the hepatitis B vaccine (RR: 2.9 (CI 1.16-7.31)) only at birth was associated with a higher risk of being under-immunized.

CONCLUSIONS:

Refusal of the hepatitis B vaccine in the nursery is associated with a risk of being under-immunized in childhood. Obstetric and pediatric providers should be aware of this association for appropriate family counseling.

01 Mar 2021·VaccineQ3 · MEDICINE

Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial

Q3 · MEDICINE

Article

Author: Luke Anschutz ; Rogelio Amisola ; Matthew Cornish ; Edward Zissman ; Armando Acevedo ; Dan Bi ; Gary Marshall ; Aarti Kulshrestha ; Ana Ugarte ; James Campbell ; John Fling ; Nicola P. Klein ; James Hedrick ; Laurent Sigg ; Shelly Senders ; William Johnston ; Michael Leonardi ; Anthony Pruitt ; David Hurley ; Regine Bataille ; Paul Wisman ; Michael Povey ; Leentje Moerman ; Joshua Fuller ; Remon Abu-Elyazeed ; Martin Levinson ; Donald Hurley ; Alan Garscadden ; Sean Livingston ; Peter Silas ; Martin Schear ; Stephen Russell ; Tina Singh ; Alvin Gabrielsen ; Julie Shepard ; Joseph Domachowske ; Paola Pirrotta ; Giancarlo Guido ; Walter Rok ; Mary Tipton ; Earl Franklin

BACKGROUND:

In response to the detection of porcine circovirus type 1 (PCV-1) in the human rotavirus vaccine (HRV), a PCV-free HRV (no detection of PCV-1 and PCV-2 according to the detection limit of tests used) was developed. Liquid (Liq) PCV-free HRV previously showed immunogenicity and safety profiles comparable to lyophilized (Lyo) HRV.

METHODS:

This was a phase 3a, randomized, single-blind study (NCT03207750) conducted in the United States. Healthy infants aged 6-12 weeks received 2 doses (0, 2 months) of either Liq PCV-free HRV or Lyo HRV with routine vaccines (0, 2, 4 months): diphtheria-tetanus-acellular pertussis, hepatitis B and inactivated poliovirus combination vaccine (DTaP-HBV-IPV), monovalent tetanus toxoid-conjugated vaccine against Haemophilus influenzae type b (Hib-TT), and 13-valent pneumococcal conjugate vaccine. Co-primary objectives were: (i) to assess non-inferiority of immune responses to routine vaccine antigens 1 month post-dose 3 following co-administration with Liq PCV-free HRV compared to Lyo HRV; (ii) to rule out a 10% decrease in seroresponse to pertussis antigens after dose 3. Other objectives were to evaluate immunogenicity and safety of HRV vaccines.

RESULTS:

Of 1272 vaccinated infants, 990 (489 in Liq PCV-free HRV and 501 in Lyo HRV group) were included in the per-protocol set. All statistical criteria were met, thus co-primary objectives were demonstrated. Seroprotection/seropositivity rates in both groups were high: 100% for diphtheria/tetanus, ≥99.3% for HBV, ≥99.8% for polio, ≥99.8% for each pertussis antigen, ≥90.8% for all pneumococcal serotypes except serotype 3 (≥69.1%), and ≥ 97.4% for Hib. Most infants seroconverted for anti-RV antibodies (76.3% of Liq PCV-free HRV and 78.9% of Lyo HRV recipients). Geometric mean concentrations/titers were comparable between groups. Incidences of adverse events and serious adverse events were similar between groups.

CONCLUSION:

Routine pediatric vaccines co-administered with Liq PCV-free HRV showed non-inferior immune responses and similar safety profiles to those following co-administration with Lyo HRV.

01 Apr 2018·VaccineQ3 · MEDICINE

A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK

Q3 · MEDICINE

Article

Author: Faust, Saul N ; Pollard, Andrew J ; Finn, Adam ; Kuriyakose, Sherine ; Snape, Matthew D ; Mesaros, Narcisa ; Tomlinson, Richard ; Marlow, Robin ; Han, Htay Htay

AIM:

To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPV_B) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPV_R (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV).

METHODS:

This phase III, open label, randomised study was conducted in the UK between April 2011 and April 2012. Children due their pre-school dTap-IPV booster vaccination were randomised 2:1 to receive one of two different dTap-IPV vaccines (dTap-IPV_B or dTap-IPV_R) with blood sample for immunogenicity assessment just prior and one month after vaccination. Immune responses to diphtheria, tetanus and polio antigens were compared between the study vaccines (inferential comparison). In the absence of an accepted pertussis correlate of protection, the immunogenicity of dTap-IPV_B vaccine against pertussis was compared with historical pertussis efficacy data (inferential comparison). Safety and reactogenicity of both study vaccines were evaluated.

RESULTS:

387 children were randomised and 385 vaccinated: 255 in the dTap-IPV_B group and 130 in the dTap-IPV_R group. Prior to vaccination, ≥76.8% of children had anti-diphtheria and ≥65.5% had anti-tetanus titres above the protection threshold; for pertussis, the pre-vaccination seropositivity rate ranged between 18.1 and 70.6%. Both vaccines were immunogenic with 99.2-100% of children achieving titres above the pre-specified seroprotection/seropositivity thresholds. One serious adverse event not considered as causally related to the study vaccination by the study investigator was reported in the dTap-IPV_B group.

CONCLUSION:

Non-inferiority of dTap-IPV_B to dTap-IPV_R was demonstrated. Both vaccines had a clinically acceptable safety and reactogenicity profile when co-administered with MMRV to children 3-4 years old.

TRIAL REGISTRATION:

NCT01245049 (ClinicalTrials.gov).

News (Medical) associated with Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

28 Jun 2022

·www.prnewswire.com

United States Human Vaccines Markets, 2018-2021 & Forecast to 2028: Approval/launches of the New Vaccines / Rising Focus on Immunization Programs / Increasing Investments and Government Support

DUBLIN, June 28, 2022 /PRNewswire/ -- The "United States Human Vaccines Market Size, Share, Top 45 Human Vaccines Brand In-depth Analysis, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 - 2028" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the United States human vaccines market is poised to grow by US$ 31,517 million by 2028, accelerating at a CAGR of 7% during the forecast period. The prominent factors that are expected to contribute to the growth of the United States human vaccines market: Increased Disease Awareness Approval/launches of the New Vaccines Rising Focus on Immunization Programs Increasing Investments and Government Support for the Vaccines Development The report contains a deep analysis of the United States human vaccines market size in terms of value. The report provides a clear insight into current and future developments of the United States vaccines market. The report also explores the detailed analysis, insights of the top 45 vaccines market assessment in the United States from 2018 to 2021, and forecasts to 2028. The report also details the latest information about the vaccine's pricing analysis, insights, and trends, and the regulatory framework of the United States human vaccines market. After conducting thorough research on the historical and current growth parameters, the growth prospects of the United States human vaccines market are obtained with maximum precision. This new 2022 market report provides a holistic analysis of the entire United States human vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States' human vaccines market. The report also tracks and analyses competitive developments, including collaboration, partnership deals, distribution, exclusive and licensing agreements, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market. The report also analyses detailed profiles of innovative and leading players with information on business overview, companies' vaccines portfolio, promising vaccines in the clinical development, and the newest developments The report will serve as a source for a 360-degree analysis, thoroughly integrating different models. This Newest and Comprehensive the United States Human Vaccines Market Research Report 2022 Delivers: Comprehensive Research Methodology of the United States Human Vaccines Market Detailed and Extensive Market Overview with Key Analyst Insights Insights about Market Determinants that are Stimulating the United States Human Vaccines Market To Analyze the Historical Growth in the Market Size of the United States Human Vaccines Market from 2018 to 2021 To Estimate and Forecast the Market Size of the United States Human Vaccines Market from 2022 to 2028 and Growth Rate until 2028 Detailed Insights of the Top 45 Human Vaccines Market Value Used in the U.S. with Six Years Forecast An Insightful Analysis of the Top 45 Vaccines Brand Market Share and Y-o-Y Growth Rate Delivers All-inclusive Insights on the Latest Pricing Analysis, Insights, and Trends Delivers an In-Depth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Human Vaccines Market An Insightful Investigation has been done on Promising Human Vaccines in the Clinical Development Delivers Comprehensive Insights into the Regulatory Framework of the United States Human Vaccines Market Tracks Competitive Developments, Approaches, Recent Industry Developments, Partnership, Collaboration Deals, Distribution, Exclusive, and Licensing Agreement A Comprehensive List of the Leading Companies along with the Analysis of their Current Vaccines Portfolio, Promising Human Vaccines in the Clinical Development, and Present Development The Report Helps Answer the Following Questions: What is the current scenario of the United States human vaccines market? What is the total market size and forecast (until 2028) of the United States human vaccines market? How big is the United States human vaccines market? At what CAGR is the U.S. human vaccines market projected to grow in the forecast period (2022-2028)? What are the leading human vaccines? What are their revenue potentials to 2028? Which human vaccine brand provides the highest market share? What is the regulatory framework in the United States vaccines market? What are the key factors driving the United States human vaccines market? What are the key challenges of the United States human vaccines market? What are the major deals and agreement happenings in the United States human vaccines market? What are the United States human vaccines pricing trends and analysis? What are the various human vaccines available in the United States? Who are the topmost market players? What are their happenings, current developments, and scenarios? How is the market predicted to develop in the future? Key Topics Covered: 1. Executive Summary 2. United States Human Vaccines Market Size and Forecast (2018 - 2028) 3. United States Human Vaccines Brand Market Share and Y-o-Y Growth (%), 2018 - 2028 4. Key Market Growth Drivers and Challenges in the United States Human Vaccines Market 4.1 Key Market Growth Drivers 4.2 Key Market Challenges 5. United States Top 45 Human Vaccines Market Value Analysis, Insights and Forecasts, 2018 - 2028 5.1 Daptacel 5.2 Quadracel 5.3 Kinrix 5.4 Vaxelis 5.5 IPOL 5.6 Vaqta 5.7 Havrix 5.8 Twinrix 5.9 Engerix B 5.10 PedvaxHIB 5.11 ActHIB 5.12 Hiberix 5.13 MenQuadfi 5.14 Tenivac 5.15 Imovax 5.16 FluMist Quadrivalent 5.17 Prevnar 13 5.18 Gardasil 9 5.19 Fluzone Quadrivalent 5.20 Flublok 5.21 Flucelvax Quadrivalent 5.22 Afluria Quadrivalent 5.23 Fluad 5.24 Varivax 5.25 Menactra 5.26 Proquad 5.27 Pneumovax 23 5.28 Fluarix 5.29 FluLaval 5.30 M-M-R II 5.31 Adacel 5.32 Boostrix 5.33 Bexsero 5.34 Menveo 5.35 Trumenba 5.36 Shingrix 5.37 Pentacel 5.38 Recombivax HB 5.39 Rotateq 5.40 Rotarix 5.41 Pediarix 5.42 Infanrix 5.43 Heplisav-B 5.44 TDVAX 5.45 BioThrax 5.46 Other Vaccines 6. United States Human Vaccines Pricing Analysis, Insights and Trends 7. Regulatory Framework of the United States Human Vaccines Market 8. Major Deals and Agreement Happenings in the Human Vaccines Market 8.1 Merger & Acquisitions 8.2 Collaboration Deals 8.3 Licensing Agreement 8.4 Exclusive Agreement 8.5 Distribution Agreement 8.6 Partnership Deals 9. Leading Companies in the United States Human Vaccines Market 9.1 Sanofi Pasteur 9.1.1 Business Overview 9.1.2 Human Vaccines Portfolio 9.1.3 Promising Human Vaccines in the Clinical Development 9.1.4 Recent Development 9.3 Merck 9.4 Pfizer 9.5 Seqirus (CSL Limited) 9.6 AstraZeneca 9.7 Dynavax Technologies Corporation 9.8 Emergent BioSolutions Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

VaccineAcquisition

02 Jun 2021

·www.biospace.com

First Six-In-One Pediatric Combination Vaccine Now Available in the United States

With a new combination vaccination available in the United States, taking your child to the doctor to get vaccines might become a little less of a hassle. Or at the very least, less frequent. On Tuesday, it was announced that a new pediatric combination vaccine is now available in the U.S. The new vaccination, dubbed VAXELIS, is indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. It is the first and only six-in-one pediatric combination vaccine available in the United States. The vaccine was developed by Merck and Sanofi Pasteur and is approved to be used as a 3-dose series in children six weeks through four years of age. “Given the potential to reduce the number of shots by as many as three in the first six months of life, as compared to pentavalent vaccines plus hepatitis B or Haemophilus influenzae type b vaccines, VAXELIS represents an important option for healthcare professionals and parents,” said Joanne Monahan, senior vice president, U.S. Vaccines, Merck. “Merck and Sanofi have been in contact with the major insurers and the appropriate pricing publications to notify them of the availability of VAXELIS, and we look forward to working with payers and providers to deliver this novel hexavalent vaccine to age-appropriate children.” While VAXELIS is the first six-in-one vaccine in the United States, combination vaccines in general have been around for a while (since the mid-1940s). In fact, some of them are so common, some people might not even realize they fall under this category. A combination vaccine is when two or more vaccines that could be given individually are put together into one shot. Some common combination shots include MMR (measles, mumps and rubella) and DTaP (diphtheria, tetanus and pertussis), although they could not be considered true combo vaccines because they aren't available as separate vaccines in the United States. Other common pediatric combination vaccines include Pediarix, ProQuad, Kinrix and Pentacel. Some of the benefits of combination vaccines include fewer shots, on-time protection, fewer visits to the doctor and less hassle overall. The U.S.-based partnership between Merck and Sanofi Pasteur under which VAXELIS was developed was established in 1991, and utilizes the companies' development, manufacturing and marketing experience for individual and combination vaccines.

Vaccine

05 Jan 2021

·www.biospace.com

New Year, New Price Hikes on Hundreds of Prescription Drugs

As the sun rose on a new year, approximately 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%. The average price increase is lower than one year ago, when the cost of drugs was raised by an average of 5.8% and 5.2% in 2019, according to an analysis. Pfizer, Sanofi and GlaxoSmithKline are some of the companies leading the way with the price increases, according to an analysis. Citing data compiled by healthcare research firm 3 Axis Advisors, Reuters reported Pfizer led the way with the highest number of drugs in its portfolio to see an increase in price. The company raised the price of more than 60 drugs by an average of 5% or less, the news agency said. Some of Pfizer’s top-selling drugs, including rheumatoid arthritis treatment Xeljanz and cancer drugs Ibrance and Inlyta, will see price increases of about 5%, Reuters reported. A Pfizer spokesperson told Reuters the company adjusted the list prices of its drugs by around 1.3% across all products in its portfolio, which is in line with inflation. “This modest increase is necessary to support investments that allow us to continue to discover new medicines and deliver those breakthroughs to the patients who need them,” Pfizer spokeswoman Amy Rose said in a statement. Sanofi will increase the price on a number of vaccines by about 5%. The France-based pharma giant will announce a number of increases later this month, but none will see a hike higher than 5.1%, Sanofi spokesperson Ashleigh Koss told Reuters. While the 3.3% price increase is lower than last year, Reuters reported that companies raised prices on more drugs this year than in 2020, an increase of about 50%. The price increases include both branded drugs, as well as generics, according to GoodRx, which is maintaining a web page with live price increase updates on its site. Prescription price increases are typically done twice per year, once in January and once in June. Most of the price increases fall below a 9.9% threshold that many companies have pledged to observe in previous years. However, there are some outliers, such as Advanz Pharma’s hypertension drug Dutoprol, which saw an increase of 31%, and Vifor’s Venofer, which is used to treat iron deficiency anemia in people with chronic kidney disease, that saw a price hike of 14.6%. Zyla Life Sciences increased the price of the anti-inflammatory pain medication indocin by 9.9%. EXELA Pharma Sciences boosted the price of protein supplement Elcys by 9.8% and Acordia Therapeutics raised the price of multiple sclerosis drug Ampyra by 9.5%, according to the GoodRx table. GSK raised the price of on two of its vaccines, Shingrix and pertussis vaccine Pediarix by 7% and 8.6 percent respectively, Reuters said. Teva Pharmaceuticals raised the price on 15 drugs, with most of those in the 5% area. However, there were a few that were more than 9%, including muscle relaxant Amrix and narcolepsy treatment Nuvigil, Reuters said. “Even amid a global pandemic, these price hikes echo an ongoing trend of drug price increases throughout past years. In January 2020, 639 drugs increased in price by an average of 6%, and 486 drugs increased by an average of 5.2% in January 2019,” GoodRx said in its announcement. While Jan. 1 price increases are expected, these latest price hikes come at a time when the nation and much of the world is still battling the COVID-19 pandemic that continues to batter global economies. In the United States, the price hikes follow new rules established by the outgoing Trump administration that attempt to control the pricing of drugs in the United States. President-elect Joe Biden has also pledged to tackle drug prices. His plan includes allowing Medicare to negotiate drug prices. More price increases are expected to be announced later this month. Most Read Today

Generic DrugVaccine

100 Deals associated with Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA12	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diphtheria	US	GlaxoSmithKline LLC	13 Dec 2002
Hepatitis B	US	GlaxoSmithKline LLC	13 Dec 2002
Poliomyelitis	US	GlaxoSmithKline LLC	13 Dec 2002
Tetanus	US	GlaxoSmithKline LLC	13 Dec 2002
Whooping Cough	US	GlaxoSmithKline LLC	13 Dec 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Haemophilus Infections	Phase 2	BE	GSK Plc	01 Mar 2003
Haemophilus Infections	Phase 2	DE	GSK Plc	01 Mar 2003
Meningitis	Phase 2	BE	GSK Plc	01 Mar 2003
Meningitis	Phase 2	DE	GSK Plc	01 Mar 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03207750 (CTgov)	Phase 3	Rotavirus Infections \| Viral gastroenteritis due to Rotavirus	1,280	human rotavirus (HRV) vaccine+Hiberix+Prevnar-13+Pediarix (HRV Porcine Circovirus (PCV)-Free Liquid Group)	wzzmujhqww(tmoagcmwkn) = qxswbczqae ymmculgrfy (rfjjttfjyv, oxernfxndh - sbhlqpjoub) View more	-	31 Oct 2019
				human rotavirus (HRV) vaccine+Hiberix+Prevnar-13+Pediarix (HRV Lyophilized Group)	wzzmujhqww(tmoagcmwkn) = urcoqiakkb ymmculgrfy (rfjjttfjyv, iqqhjnnhib - qyqwkjfecq) View more
NCT00129116 (CTgov)	Phase 2	Meningitis \| Haemophilus Infections	388	Hib-MenCY-TT vaccine+Infanrix penta ® (Menhibrix F1/Infanrix-penta Group)	vuukxutuzl(xqznmgbqfc) = bdtfusdajp jcheysncba (nigqrtlcak, fowqrzclju - rcapwahrom) View more	-	23 Jul 2012
				Hib-MenCY-TT vaccine+Infanrix penta ® (Menhibrix F2/Infanrix-penta Group)	vuukxutuzl(xqznmgbqfc) = pmlwedvdjc jcheysncba (nigqrtlcak, ogwlawkylv - tgqscwlrzz) View more
NCT00134719 (CTgov)	Phase 2	Meningitis \| Haemophilus Infections	1,104	Varivax®+MenHibrix (Hib-MenCY-TT)+M-M-R®II+Prevenar®+Infanrix® Penta (MenHibrix Group)	rxbsenchis(xuycdgvnxn) = iurkgyslxb tdwiuigoql (fvoyxjtfna, utdhpmbmny - wxafayyodq) View more	-	20 Jul 2012
				Meningitec®+ActHIB®+MenHibrix (Hib-MenCY-TT)+M-M-R®II+Prevenar®+Infanrix® Penta (ActHIB + Meningitec Group)	tvbifibfbg(hpinsvnxfb) = lxnvtfgxvb yiovkiipno (lupljebwat, jvpiutkant - fzxzllveqd) View more
NCT00891176 (CTgov)	Phase 3	Meningitis \| Haemophilus Infections	582	Pneumococcal conjugate vaccine GSK1024850A+MeningitecTM+InfanrixTM hexa+InfanrixTM IPV/Hib (Synflorix-Meningitec Group)	cfjchjfald(hczpycjldw) = akiblwfppx agovpbsrjp (dikiybijjz, vavyskeccu - ecjoveeilp) View more	-	23 Dec 2010
				Pneumococcal conjugate vaccine GSK1024850A+InfanrixTM hexa+InfanrixTM IPV/Hib+NeisVac-CTM (Synflorix-NeisVac-C Group)	cfjchjfald(hczpycjldw) = treibwwvzl agovpbsrjp (dikiybijjz, rlbfsglqiu - ecosqzabtt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (GlaxoSmithKline Plc)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation